Search Results

You searched for : nintedanib

	Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg According to IQVIATM sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales ... Jun 25
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases Cipla Limited today announced that it has launched generic Nintedanib for the treatment of Idiopathic Pulmonary Fibrosis ... Oct 21
	Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis Glenmark being a leader in the area of respiratory has been amongst the first to launch the branded generic version for the treatment of Pulmonary ... Oct 14
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1 New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive ... Oct 01
6 Matching result(s) found!

-Advertisements-

Trending Now
	FLO organized a session with two of the top VCs in India on "The Journey of an Idea"June 06, 2024
	FTCCI organised a Workshop on "Opportunities in Food Processing"June 06, 2024
	Roundtable conference on Ethical Business Practices heldJune 06, 2024
	Magniflex India makes a sustainable leap forward with the launch of MagnigeoJune 06, 2024
	Unlocking the Secrets of Sleep: How Rest Impacts Brain Health and Waste RemovalJune 06, 2024
	ICMR Warns Against Overheating Non-Stick Pans: Tips to Prevent Toxin ExposureJune 06, 2024
	Promising New HIV Vaccine Candidate Shows Early Success: A Hopeful Step in HIV ResearchJune 06, 2024
	MAGGI makes an appeal on World Environment Day: ‘2-Min for the Environment: Everyone. Everyday.’June 05, 2024
	HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver CongressJune 05, 2024
	FSSAI Enforces Transparency: No More '100% Fruit Juice' Claims on Reconstituted ProductsJune 05, 2024
	Is Omega-3 Fatty Acid and Fish Oil Good for Your Heart? Recent Study Suggest Mixed ResultsJune 05, 2024
	Neonatal Unit Fire: Court Dismisses Bail for Unqualified Ayurvedic DoctorJune 05, 2024
	Protect the medicines that protect usJune 04, 2024
	New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for BiotechsJune 04, 2024
	Indonesia is enforcing stronger anti-tobacco measures despite industry interferenceJune 04, 2024
	How will a NDA win in Lok Sabha polls impact healthcare market June 04, 2024
	Strokes Aren’t Just for the Elderly: A 33-Year-Old’s Survival StoryJune 04, 2024
	From Lower Back Pain to Cardiovascular Disease: Addressing the Health Divide Between Men and WomenJune 04, 2024
	Attack on Doctor at GB Hospital Sparks Outrage in Medical CommunityJune 04, 2024
	How Age Discrimination Impacts Indian Employees: A Closer LookJune 04, 2024

Search Results

Glenmark Pharmaceuticals receives ANDA tentative approval for Nintedanib Capsules, 100 mg and 150 mg

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Cipla launches Nintib to treat Idiopathic Pulmonary Fibrosis, in continuation of its fight against rare lung diseases

Glenmark introduces a generic version of NINDANIB for the treatment of Pulmonary Fibrosis

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

INBUILDÂ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1

Trending Now